Heparin And Hyperkalemia Jun 2026

The risk and severity of hyperkalemia vary depending on the formulation of heparin used.

National Institutes of Health (.gov)https://pmc.ncbi.nlm.nih.gov Heparin‐induced hyperkalemia, can LMWH cause ... - PMC heparin and hyperkalemia

By inhibiting this enzyme, heparin reduces the production of aldosterone without significantly affecting cortisol or androgen synthesis. The risk and severity of hyperkalemia vary depending

Heparin is a widely utilized anticoagulant in both prophylactic and therapeutic settings. While its hematologic side effect, heparin-induced thrombocytopenia (HIT), is well-documented, its potential to induce hyperkalemia remains an under-recognized clinical phenomenon. Heparin inhibits the biosynthesis of aldosterone, the primary mineralocorticoid responsible for potassium homeostasis. This inhibition can lead to a state of secondary hypoaldosteronism, resulting in reduced renal potassium excretion and subsequent hyperkalemia. This paper reviews the pathophysiology of heparin-induced hyperkalemia, distinguishes between the risks associated with unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH), and outlines the clinical management strategies for at-risk patients. Heparin is a widely utilized anticoagulant in both

Hyperkalemia is a condition where the potassium levels in the blood become too high. Normal potassium levels range from 3.5 to 5.0 mmol/L. When potassium levels exceed 5.5 mmol/L, it can lead to muscle weakness, fatigue, and heart arrhythmias. In severe cases, hyperkalemia can cause cardiac arrest.